Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Expert Review of Anticancer Therapy|April 17, 2012
The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancerRandall J Kimple, Suzanne Russo, Arta Monjazeb, et al.
Journal of Visualized Experiments : Jove|March 6, 2023
Establishment and Culture of Patient-Derived Breast OrganoidsDisha Aggarwal, Suzanne Russo, Payal Naik, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2006
Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylaseMuhammad Wasif Saif, Glenda Black, Martin Johnson, et al.
Molecular Therapy. Oncology|November 17, 2025
Longitudinal tracking of MALAT1 level over a breast cancer patient's course of treatment and disease progressionDisha Aggarwal, Tse-Luen Wee, Shuchismita Satpathy, et al.
Lung Cancer (Amsterdam, Netherlands)|November 20, 2013
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancerJun Zhang, Hiram A Gay, Suzanne Russo, et al.
American Journal of Surgery|December 25, 2007
Prognostic factors and preoperative radiation therapy associated with sphincter preservation in patients with resectable rectal cancerJ Harrison Howard, Quintin Gonzalez, J Pablo Arnoletti, et al.
Pediatric Neurology|May 4, 2019
A Review of Chronic Leukoencephalopathy among Survivors of Childhood CancerSonia Partap, Suzanne Russo, Bijan Esfahani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitorsJessica K Altman, Antonella Sassano, Surinder Kaur, et al.
Cancer Journal (Sudbury, Mass.)|September 1, 2007
Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylaseMuhammad Wasif Saif, Glenda Black, Shalija Roy, et al.
Molecular Cancer Therapeutics|February 28, 2013
A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagyEvrim Gurpinar, William E Grizzle, John J Shacka, et al.
Pageof 6